OMER

Business Context and Reporting Period

Company: Omeros Corporation (OMEROS CORP)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on inflammation, coagulopathies, and central nervous system disorders. The company operates as a development-stage entity with no products approved for commercial sale. Its primary pipeline includes the PharmacoSurgery platform (OMS103HP, OMS302, OMS201) and various preclinical programs (GPCR, PDE10, PDE7, MASP-2).

Key Financial Metrics

Note: Revenue consists primarily of grant funding and revenue recognized from the Vulcan and LSDF agreements. The company has not generated revenue from product sales.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 228% to $1.2 million from $378,000 in Q1 2010. This was driven by $1.0 million in revenue recognized from the Vulcan and LSDF funding agreements for the GPCR program, partially offset by the completion of NIH-funded preclinical research.
• Operating Expenses: Total operating expenses rose to $7.7 million from $6.8 million. Research and Development (R&D) expenses increased to $5.4 million due to higher contract service costs for clinical trials and additional employee costs. General and Administrative (G&A) expenses increased to $2.3 million, primarily due to higher legal and patent costs.
• Debt Financing: In March 2011, the company borrowed the second tranche ($10.0 million) of a $20.0 million credit facility with Oxford Finance Corporation. Total notes payable increased significantly from $10.3 million at year-end 2010 to $20.3 million at March 31, 2011.
• Cash Flow: Net cash used in operating activities was $7.9 million, compared to $7.6 million in the prior year. Net cash provided by financing activities was $10.2 million, driven by the new debt borrowing.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($43.6 million) are sufficient to fund operations for at least the next 12 months.
• Product Pipeline:
  • OMS103HP: Failed to meet efficacy endpoints in a Phase 3 ACL reconstruction trial. The company has no plans for further ACL trials but is preparing to begin enrollment in a Phase 3 partial meniscectomy trial in Q2 2011.
  • OMS302: Completed a Phase 2b cataract surgery trial showing statistically significant benefits in pupil dilation and pain reduction. The company is determining next steps following an end-of-Phase 2 meeting with the FDA.
  • OMS201: Completed a Phase 1/2 urological trial showing safety; efficacy trials have not yet been conducted.
• Commercialization: The company does not anticipate generating revenue from product sales until 2013 at the earliest.

Risks and Contingencies

• Legal Proceedings: The company is defending a lawsuit filed by former CFO Richard J. Klein alleging violations of the Federal False Claims Act regarding NIH grants. The company denies the allegations and believes it has meritorious defenses, but the outcome is uncertain.
• Debt Covenants: The Oxford loan agreement contains restrictive covenants and a "material adverse change" default clause. Default could result in the acceleration of repayment obligations.
• Capital Requirements: Future funding needs depend on clinical trial progress. If capital is insufficient, the company may need to delay programs or seek equity/debt financing, which could result in dilution.
• Equity Line: In May 2011, the company entered into an equity line facility with Azimuth Opportunity, Ltd., allowing for the sale of up to $40.0 million of common stock over 24 months. No funds had been drawn as of the filing date.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $43.6 million cash balance against projected burn rates, considering the $20.3 million debt obligation and upcoming Phase 3 trial costs.
• Clinical Trial Status: Confirm the timeline and enrollment status for the OMS103HP partial meniscectomy Phase 3 trial and the FDA's feedback on OMS302.
• Debt Terms: Review the specific covenants and prepayment penalties associated with the Oxford Finance Corporation loan facility.
• Legal Exposure: Monitor the status of the Richard J. Klein litigation and any potential financial impact from the qui tam claim.
• Revenue Recognition: Understand the specific milestones and expense reimbursement triggers for the Vulcan and LSDF funding agreements, which currently drive revenue.